Advertisement

Index by author

April 01, 1995; Volume 47,Issue 4

A

  1. Abraham, P

    1. Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester.
      J W Boja, J L Cadet, T A Kopajtic, J Lever, H H Seltzman, C D Wyrick, A H Lewin, P Abraham and F I Carroll
      Molecular Pharmacology April 1995, 47 (4) 779-786;

  2. Aduma, P

    1. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates.
      P Aduma, M C Connelly, R V Srinivas and A Fridland
      Molecular Pharmacology April 1995, 47 (4) 816-822;

  3. Allen, R A

    1. Stimulation of type II adenylyl cyclase by chemoattractant formyl peptide and C5a receptors.
      R C Tsu, R A Allen and Y H Wong
      Molecular Pharmacology April 1995, 47 (4) 835-841;

  4. Andexinger, S

    1. Sequestration and recycling of beta 2-adrenergic receptors permit receptor resensitization.
      S Pippig, S Andexinger and M J Lohse
      Molecular Pharmacology April 1995, 47 (4) 666-676;

  5. Asselin, J

    1. Ethylene glycol bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) and the tyrphostin ST271 inhibit phospholipase C in human platelets by preventing Ca2+ entry.
      S P Watson, A Poole and J Asselin
      Molecular Pharmacology April 1995, 47 (4) 823-830;

  6. Aversa, C R

    1. Cloning and expression of an endothelin receptor subtype B from human prostate that mediates contraction.
      M L Webb, C C Chao, M Rizzo, R A Shapiro, M Neubauer, E C Liu, C R Aversa, R J Brittain and B Treiger
      Molecular Pharmacology April 1995, 47 (4) 730-737;

B

  1. Basha, F

    1. Novel potent and selective inhibitors of inducible nitric oxide synthase.
      M Nakane, V Klinghofer, J E Kuk, J L Donnelly, G P Budzik, J S Pollock, F Basha and G W Carter
      Molecular Pharmacology April 1995, 47 (4) 831-834;

  2. Becker, M A

    1. Inhibition of human 5-phosphoribosyl-1-pyrophosphate synthetase by 4-amino-8-(beta-D-ribofuranosylamino)-pyrimido[5,4-d]pyrimidine-5'- monophosphate: evidence for interaction at the ADP allosteric site.
      D W Fry, M A Becker and R L Switzer
      Molecular Pharmacology April 1995, 47 (4) 810-815;

  3. Ber, E

    1. Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
      M A Cascieri, L L Shiao, S G Mills, M MacCoss, C J Swain, H Yu, E Ber, S Sadowski, M T Wu and C D Strader
      Molecular Pharmacology April 1995, 47 (4) 660-665;

  4. Berg, D K

    1. Novel subpopulation of neuronal acetylcholine receptors among those binding alpha-bungarotoxin.
      P C Pugh, R A Corriveau, W G Conroy and D K Berg
      Molecular Pharmacology April 1995, 47 (4) 717-725;

  5. Billingsley, M L

    1. Tau phosphorylation in brain slices: pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase.
      T D Garver, G A Oyler, K A Harris, R Polavarapu, Z Damuni, R A Lehman and M L Billingsley
      Molecular Pharmacology April 1995, 47 (4) 745-756;

  6. Boja, J W

    1. Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester.
      J W Boja, J L Cadet, T A Kopajtic, J Lever, H H Seltzman, C D Wyrick, A H Lewin, P Abraham and F I Carroll
      Molecular Pharmacology April 1995, 47 (4) 779-786;

  7. Brady, C L

    1. Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
      S Houssami, D M Findlay, C L Brady, T J Martin, R M Epand, E E Moore, E Murayama, T Tamura, R C Orlowski and P M Sexton
      Molecular Pharmacology April 1995, 47 (4) 798-809;

  8. Brandt, T L

    1. Topoisomerase II alpha promoter trans-activation early in monocytic differentiation of HL-60 human leukemia cells.
      D J Fraser, T L Brandt and D J Kroll
      Molecular Pharmacology April 1995, 47 (4) 696-706;

  9. Bresnick, E

    1. Regulation of the constitutive expression of the human CYP1A2 gene: cis elements and their interactions with proteins.
      I Chung and E Bresnick
      Molecular Pharmacology April 1995, 47 (4) 677-685;

  10. Brittain, R J

    1. Cloning and expression of an endothelin receptor subtype B from human prostate that mediates contraction.
      M L Webb, C C Chao, M Rizzo, R A Shapiro, M Neubauer, E C Liu, C R Aversa, R J Brittain and B Treiger
      Molecular Pharmacology April 1995, 47 (4) 730-737;

  11. Brüne, B

    1. Nitric oxide-induced apoptosis in RAW 264.7 macrophages is antagonized by protein kinase C- and protein kinase A-activating compounds.
      U K Messmer, E G Lapetina and B Brüne
      Molecular Pharmacology April 1995, 47 (4) 757-765;

  12. Budzik, G P

    1. Novel potent and selective inhibitors of inducible nitric oxide synthase.
      M Nakane, V Klinghofer, J E Kuk, J L Donnelly, G P Budzik, J S Pollock, F Basha and G W Carter
      Molecular Pharmacology April 1995, 47 (4) 831-834;

  13. Busconi, L

    1. Recombinant endothelial nitric oxide synthase: post-translational modifications in a baculovirus expression system.
      L Busconi and T Michel
      Molecular Pharmacology April 1995, 47 (4) 655-659;

C

  1. Cadet, J L

    1. Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester.
      J W Boja, J L Cadet, T A Kopajtic, J Lever, H H Seltzman, C D Wyrick, A H Lewin, P Abraham and F I Carroll
      Molecular Pharmacology April 1995, 47 (4) 779-786;

  2. Carroll, F I

    1. Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester.
      J W Boja, J L Cadet, T A Kopajtic, J Lever, H H Seltzman, C D Wyrick, A H Lewin, P Abraham and F I Carroll
      Molecular Pharmacology April 1995, 47 (4) 779-786;

  3. Carter, G W

    1. Novel potent and selective inhibitors of inducible nitric oxide synthase.
      M Nakane, V Klinghofer, J E Kuk, J L Donnelly, G P Budzik, J S Pollock, F Basha and G W Carter
      Molecular Pharmacology April 1995, 47 (4) 831-834;

  4. Cascieri, M A

    1. Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
      M A Cascieri, L L Shiao, S G Mills, M MacCoss, C J Swain, H Yu, E Ber, S Sadowski, M T Wu and C D Strader
      Molecular Pharmacology April 1995, 47 (4) 660-665;

  5. Castro, M A

    1. Antibodies to the cloned mu-opioid receptor detect various molecular weight forms in areas of mouse brain.
      J Garzon, J L Juarros, M A Castro and P Sanchez-Blazquez
      Molecular Pharmacology April 1995, 47 (4) 738-744;

  6. Chao, C C

    1. Cloning and expression of an endothelin receptor subtype B from human prostate that mediates contraction.
      M L Webb, C C Chao, M Rizzo, R A Shapiro, M Neubauer, E C Liu, C R Aversa, R J Brittain and B Treiger
      Molecular Pharmacology April 1995, 47 (4) 730-737;

  7. Chung, I

    1. Regulation of the constitutive expression of the human CYP1A2 gene: cis elements and their interactions with proteins.
      I Chung and E Bresnick
      Molecular Pharmacology April 1995, 47 (4) 677-685;

  8. Connelly, M C

    1. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates.
      P Aduma, M C Connelly, R V Srinivas and A Fridland
      Molecular Pharmacology April 1995, 47 (4) 816-822;

  9. Conroy, W G

    1. Novel subpopulation of neuronal acetylcholine receptors among those binding alpha-bungarotoxin.
      P C Pugh, R A Corriveau, W G Conroy and D K Berg
      Molecular Pharmacology April 1995, 47 (4) 717-725;

  10. Corriveau, R A

    1. Novel subpopulation of neuronal acetylcholine receptors among those binding alpha-bungarotoxin.
      P C Pugh, R A Corriveau, W G Conroy and D K Berg
      Molecular Pharmacology April 1995, 47 (4) 717-725;

D

  1. Damuni, Z

    1. Tau phosphorylation in brain slices: pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase.
      T D Garver, G A Oyler, K A Harris, R Polavarapu, Z Damuni, R A Lehman and M L Billingsley
      Molecular Pharmacology April 1995, 47 (4) 745-756;

  2. Díaz, R S

    1. Protein-independent lead permeation through myelin lipid liposomes.
      R S Díaz and J Monreal
      Molecular Pharmacology April 1995, 47 (4) 766-771;

  3. Donnelly, J L

    1. Novel potent and selective inhibitors of inducible nitric oxide synthase.
      M Nakane, V Klinghofer, J E Kuk, J L Donnelly, G P Budzik, J S Pollock, F Basha and G W Carter
      Molecular Pharmacology April 1995, 47 (4) 831-834;

E

  1. Eddlestone, G T

    1. Mastoparan increases the intracellular free calcium concentration in two insulin-secreting cell lines by inhibition of ATP-sensitive potassium channels.
      G T Eddlestone, M Komatsu, L Shen and G W Sharp
      Molecular Pharmacology April 1995, 47 (4) 787-797;

  2. Epand, R M

    1. Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
      S Houssami, D M Findlay, C L Brady, T J Martin, R M Epand, E E Moore, E Murayama, T Tamura, R C Orlowski and P M Sexton
      Molecular Pharmacology April 1995, 47 (4) 798-809;

F

  1. Feldman, R I

    1. Differential activation of human gastrin-releasing peptide receptor-mediated responses by bombesin analogs.
      J M Wu, D O Hoang and R I Feldman
      Molecular Pharmacology April 1995, 47 (4) 871-881;

  2. Findlay, D M

    1. Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
      S Houssami, D M Findlay, C L Brady, T J Martin, R M Epand, E E Moore, E Murayama, T Tamura, R C Orlowski and P M Sexton
      Molecular Pharmacology April 1995, 47 (4) 798-809;

  3. Fleming, W W

    1. Adaptive supersensitivity and the Na+/K+ pump in the guinea pig vas deferens: time course of the decline in the alpha 2 subunit.
      K M Hershman, D A Taylor and W W Fleming
      Molecular Pharmacology April 1995, 47 (4) 726-729;

  4. Fraser, D J

    1. Topoisomerase II alpha promoter trans-activation early in monocytic differentiation of HL-60 human leukemia cells.
      D J Fraser, T L Brandt and D J Kroll
      Molecular Pharmacology April 1995, 47 (4) 696-706;

  5. Fridland, A

    1. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates.
      P Aduma, M C Connelly, R V Srinivas and A Fridland
      Molecular Pharmacology April 1995, 47 (4) 816-822;

  6. Friedman, E

    1. Beta-adrenoceptor-G alpha S coupling decreases with age in rat aorta.
      H Gurdal, E Friedman and M D Johnson
      Molecular Pharmacology April 1995, 47 (4) 772-778;

  7. Fry, D W

    1. Inhibition of human 5-phosphoribosyl-1-pyrophosphate synthetase by 4-amino-8-(beta-D-ribofuranosylamino)-pyrimido[5,4-d]pyrimidine-5'- monophosphate: evidence for interaction at the ADP allosteric site.
      D W Fry, M A Becker and R L Switzer
      Molecular Pharmacology April 1995, 47 (4) 810-815;

G

  1. Garver, T D

    1. Tau phosphorylation in brain slices: pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase.
      T D Garver, G A Oyler, K A Harris, R Polavarapu, Z Damuni, R A Lehman and M L Billingsley
      Molecular Pharmacology April 1995, 47 (4) 745-756;

  2. Garzon, J

    1. Antibodies to the cloned mu-opioid receptor detect various molecular weight forms in areas of mouse brain.
      J Garzon, J L Juarros, M A Castro and P Sanchez-Blazquez
      Molecular Pharmacology April 1995, 47 (4) 738-744;

  3. Gurdal, H

    1. Beta-adrenoceptor-G alpha S coupling decreases with age in rat aorta.
      H Gurdal, E Friedman and M D Johnson
      Molecular Pharmacology April 1995, 47 (4) 772-778;

H

  1. Harris, K A

    1. Tau phosphorylation in brain slices: pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase.
      T D Garver, G A Oyler, K A Harris, R Polavarapu, Z Damuni, R A Lehman and M L Billingsley
      Molecular Pharmacology April 1995, 47 (4) 745-756;

  2. Hershman, K M

    1. Adaptive supersensitivity and the Na+/K+ pump in the guinea pig vas deferens: time course of the decline in the alpha 2 subunit.
      K M Hershman, D A Taylor and W W Fleming
      Molecular Pharmacology April 1995, 47 (4) 726-729;

  3. Hoang, D O

    1. Differential activation of human gastrin-releasing peptide receptor-mediated responses by bombesin analogs.
      J M Wu, D O Hoang and R I Feldman
      Molecular Pharmacology April 1995, 47 (4) 871-881;

  4. Houssami, S

    1. Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
      S Houssami, D M Findlay, C L Brady, T J Martin, R M Epand, E E Moore, E Murayama, T Tamura, R C Orlowski and P M Sexton
      Molecular Pharmacology April 1995, 47 (4) 798-809;

I

  1. Ishimoto, H

    1. Extracellular ATP stimulates adenylyl cyclase and phospholipase C through distinct purinoceptors in NG108-15 cells.
      I Matsuoka, Q Zhou, H Ishimoto and H Nakanishi
      Molecular Pharmacology April 1995, 47 (4) 855-862;

J

  1. Johnson, M D

    1. Beta-adrenoceptor-G alpha S coupling decreases with age in rat aorta.
      H Gurdal, E Friedman and M D Johnson
      Molecular Pharmacology April 1995, 47 (4) 772-778;

  2. Juarros, J L

    1. Antibodies to the cloned mu-opioid receptor detect various molecular weight forms in areas of mouse brain.
      J Garzon, J L Juarros, M A Castro and P Sanchez-Blazquez
      Molecular Pharmacology April 1995, 47 (4) 738-744;

K

  1. Kelly, K M

    1. Comparison of fura-2 imaging and electrophysiological analysis of murine calcium channel alpha 1 subunits coexpressed with novel beta 2 subunit isoforms.
      E Massa, K M Kelly, D I Yule, R L MacDonald and M D Uhler
      Molecular Pharmacology April 1995, 47 (4) 707-716;

  2. Kim, G

    1. Effects of chromium on basal and insulin-induced tyrosine phosphorylation in H4 hepatoma cells: comparison with phorbol-12-myristate-13-acetate and sodium orthovanadate.
      E J Yurkow and G Kim
      Molecular Pharmacology April 1995, 47 (4) 686-695;

  3. Klinghofer, V

    1. Novel potent and selective inhibitors of inducible nitric oxide synthase.
      M Nakane, V Klinghofer, J E Kuk, J L Donnelly, G P Budzik, J S Pollock, F Basha and G W Carter
      Molecular Pharmacology April 1995, 47 (4) 831-834;

  4. Komatsu, M

    1. Mastoparan increases the intracellular free calcium concentration in two insulin-secreting cell lines by inhibition of ATP-sensitive potassium channels.
      G T Eddlestone, M Komatsu, L Shen and G W Sharp
      Molecular Pharmacology April 1995, 47 (4) 787-797;

  5. Kopajtic, T A

    1. Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester.
      J W Boja, J L Cadet, T A Kopajtic, J Lever, H H Seltzman, C D Wyrick, A H Lewin, P Abraham and F I Carroll
      Molecular Pharmacology April 1995, 47 (4) 779-786;

  6. Kroll, D J

    1. Topoisomerase II alpha promoter trans-activation early in monocytic differentiation of HL-60 human leukemia cells.
      D J Fraser, T L Brandt and D J Kroll
      Molecular Pharmacology April 1995, 47 (4) 696-706;

  7. Kuk, J E

    1. Novel potent and selective inhibitors of inducible nitric oxide synthase.
      M Nakane, V Klinghofer, J E Kuk, J L Donnelly, G P Budzik, J S Pollock, F Basha and G W Carter
      Molecular Pharmacology April 1995, 47 (4) 831-834;

  8. Kusaka, M

    1. Direct block of calcium channels by dioctanoylglycerol in pregnant rat myometrial cells.
      M Kusaka and N Sperelakis
      Molecular Pharmacology April 1995, 47 (4) 842-847;

L

  1. Lapetina, E G

    1. Nitric oxide-induced apoptosis in RAW 264.7 macrophages is antagonized by protein kinase C- and protein kinase A-activating compounds.
      U K Messmer, E G Lapetina and B Brüne
      Molecular Pharmacology April 1995, 47 (4) 757-765;

  2. Lehman, R A

    1. Tau phosphorylation in brain slices: pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase.
      T D Garver, G A Oyler, K A Harris, R Polavarapu, Z Damuni, R A Lehman and M L Billingsley
      Molecular Pharmacology April 1995, 47 (4) 745-756;

  3. Lever, J

    1. Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester.
      J W Boja, J L Cadet, T A Kopajtic, J Lever, H H Seltzman, C D Wyrick, A H Lewin, P Abraham and F I Carroll
      Molecular Pharmacology April 1995, 47 (4) 779-786;

  4. Lewin, A H

    1. Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester.
      J W Boja, J L Cadet, T A Kopajtic, J Lever, H H Seltzman, C D Wyrick, A H Lewin, P Abraham and F I Carroll
      Molecular Pharmacology April 1995, 47 (4) 779-786;

  5. Liu, E C

    1. Cloning and expression of an endothelin receptor subtype B from human prostate that mediates contraction.
      M L Webb, C C Chao, M Rizzo, R A Shapiro, M Neubauer, E C Liu, C R Aversa, R J Brittain and B Treiger
      Molecular Pharmacology April 1995, 47 (4) 730-737;

  6. Lohse, M J

    1. Sequestration and recycling of beta 2-adrenergic receptors permit receptor resensitization.
      S Pippig, S Andexinger and M J Lohse
      Molecular Pharmacology April 1995, 47 (4) 666-676;

M

  1. MacCoss, M

    1. Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
      M A Cascieri, L L Shiao, S G Mills, M MacCoss, C J Swain, H Yu, E Ber, S Sadowski, M T Wu and C D Strader
      Molecular Pharmacology April 1995, 47 (4) 660-665;

  2. MacDonald, R L

    1. Comparison of fura-2 imaging and electrophysiological analysis of murine calcium channel alpha 1 subunits coexpressed with novel beta 2 subunit isoforms.
      E Massa, K M Kelly, D I Yule, R L MacDonald and M D Uhler
      Molecular Pharmacology April 1995, 47 (4) 707-716;

  3. Martin, T J

    1. Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
      S Houssami, D M Findlay, C L Brady, T J Martin, R M Epand, E E Moore, E Murayama, T Tamura, R C Orlowski and P M Sexton
      Molecular Pharmacology April 1995, 47 (4) 798-809;

  4. Massa, E

    1. Comparison of fura-2 imaging and electrophysiological analysis of murine calcium channel alpha 1 subunits coexpressed with novel beta 2 subunit isoforms.
      E Massa, K M Kelly, D I Yule, R L MacDonald and M D Uhler
      Molecular Pharmacology April 1995, 47 (4) 707-716;

  5. Matsuoka, I

    1. Extracellular ATP stimulates adenylyl cyclase and phospholipase C through distinct purinoceptors in NG108-15 cells.
      I Matsuoka, Q Zhou, H Ishimoto and H Nakanishi
      Molecular Pharmacology April 1995, 47 (4) 855-862;

  6. Messmer, U K

    1. Nitric oxide-induced apoptosis in RAW 264.7 macrophages is antagonized by protein kinase C- and protein kinase A-activating compounds.
      U K Messmer, E G Lapetina and B Brüne
      Molecular Pharmacology April 1995, 47 (4) 757-765;

  7. Michel, T

    1. Recombinant endothelial nitric oxide synthase: post-translational modifications in a baculovirus expression system.
      L Busconi and T Michel
      Molecular Pharmacology April 1995, 47 (4) 655-659;

  8. Mills, S G

    1. Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
      M A Cascieri, L L Shiao, S G Mills, M MacCoss, C J Swain, H Yu, E Ber, S Sadowski, M T Wu and C D Strader
      Molecular Pharmacology April 1995, 47 (4) 660-665;

  9. Monreal, J

    1. Protein-independent lead permeation through myelin lipid liposomes.
      R S Díaz and J Monreal
      Molecular Pharmacology April 1995, 47 (4) 766-771;

  10. Moore, E E

    1. Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
      S Houssami, D M Findlay, C L Brady, T J Martin, R M Epand, E E Moore, E Murayama, T Tamura, R C Orlowski and P M Sexton
      Molecular Pharmacology April 1995, 47 (4) 798-809;

  11. Murayama, E

    1. Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
      S Houssami, D M Findlay, C L Brady, T J Martin, R M Epand, E E Moore, E Murayama, T Tamura, R C Orlowski and P M Sexton
      Molecular Pharmacology April 1995, 47 (4) 798-809;

N

  1. Nahorski, S R

    1. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
      J R Traynor and S R Nahorski
      Molecular Pharmacology April 1995, 47 (4) 848-854;

  2. Nakane, M

    1. Novel potent and selective inhibitors of inducible nitric oxide synthase.
      M Nakane, V Klinghofer, J E Kuk, J L Donnelly, G P Budzik, J S Pollock, F Basha and G W Carter
      Molecular Pharmacology April 1995, 47 (4) 831-834;

  3. Nakanishi, H

    1. Extracellular ATP stimulates adenylyl cyclase and phospholipase C through distinct purinoceptors in NG108-15 cells.
      I Matsuoka, Q Zhou, H Ishimoto and H Nakanishi
      Molecular Pharmacology April 1995, 47 (4) 855-862;

  4. Neubauer, M

    1. Cloning and expression of an endothelin receptor subtype B from human prostate that mediates contraction.
      M L Webb, C C Chao, M Rizzo, R A Shapiro, M Neubauer, E C Liu, C R Aversa, R J Brittain and B Treiger
      Molecular Pharmacology April 1995, 47 (4) 730-737;

O

  1. Orlowski, R C

    1. Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
      S Houssami, D M Findlay, C L Brady, T J Martin, R M Epand, E E Moore, E Murayama, T Tamura, R C Orlowski and P M Sexton
      Molecular Pharmacology April 1995, 47 (4) 798-809;

  2. Oyler, G A

    1. Tau phosphorylation in brain slices: pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase.
      T D Garver, G A Oyler, K A Harris, R Polavarapu, Z Damuni, R A Lehman and M L Billingsley
      Molecular Pharmacology April 1995, 47 (4) 745-756;

P

  1. Pippig, S

    1. Sequestration and recycling of beta 2-adrenergic receptors permit receptor resensitization.
      S Pippig, S Andexinger and M J Lohse
      Molecular Pharmacology April 1995, 47 (4) 666-676;

  2. Polavarapu, R

    1. Tau phosphorylation in brain slices: pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase.
      T D Garver, G A Oyler, K A Harris, R Polavarapu, Z Damuni, R A Lehman and M L Billingsley
      Molecular Pharmacology April 1995, 47 (4) 745-756;

  3. Pollock, J S

    1. Novel potent and selective inhibitors of inducible nitric oxide synthase.
      M Nakane, V Klinghofer, J E Kuk, J L Donnelly, G P Budzik, J S Pollock, F Basha and G W Carter
      Molecular Pharmacology April 1995, 47 (4) 831-834;

  4. Poole, A

    1. Ethylene glycol bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) and the tyrphostin ST271 inhibit phospholipase C in human platelets by preventing Ca2+ entry.
      S P Watson, A Poole and J Asselin
      Molecular Pharmacology April 1995, 47 (4) 823-830;

  5. Pugh, P C

    1. Novel subpopulation of neuronal acetylcholine receptors among those binding alpha-bungarotoxin.
      P C Pugh, R A Corriveau, W G Conroy and D K Berg
      Molecular Pharmacology April 1995, 47 (4) 717-725;

R

  1. Rizzo, M

    1. Cloning and expression of an endothelin receptor subtype B from human prostate that mediates contraction.
      M L Webb, C C Chao, M Rizzo, R A Shapiro, M Neubauer, E C Liu, C R Aversa, R J Brittain and B Treiger
      Molecular Pharmacology April 1995, 47 (4) 730-737;

S

  1. Sadowski, S

    1. Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
      M A Cascieri, L L Shiao, S G Mills, M MacCoss, C J Swain, H Yu, E Ber, S Sadowski, M T Wu and C D Strader
      Molecular Pharmacology April 1995, 47 (4) 660-665;

  2. Sanchez-Blazquez, P

    1. Antibodies to the cloned mu-opioid receptor detect various molecular weight forms in areas of mouse brain.
      J Garzon, J L Juarros, M A Castro and P Sanchez-Blazquez
      Molecular Pharmacology April 1995, 47 (4) 738-744;

  3. Seltzman, H H

    1. Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester.
      J W Boja, J L Cadet, T A Kopajtic, J Lever, H H Seltzman, C D Wyrick, A H Lewin, P Abraham and F I Carroll
      Molecular Pharmacology April 1995, 47 (4) 779-786;

  4. Sexton, P M

    1. Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
      S Houssami, D M Findlay, C L Brady, T J Martin, R M Epand, E E Moore, E Murayama, T Tamura, R C Orlowski and P M Sexton
      Molecular Pharmacology April 1995, 47 (4) 798-809;

  5. Shapiro, R A

    1. Cloning and expression of an endothelin receptor subtype B from human prostate that mediates contraction.
      M L Webb, C C Chao, M Rizzo, R A Shapiro, M Neubauer, E C Liu, C R Aversa, R J Brittain and B Treiger
      Molecular Pharmacology April 1995, 47 (4) 730-737;

  6. Sharp, G W

    1. Mastoparan increases the intracellular free calcium concentration in two insulin-secreting cell lines by inhibition of ATP-sensitive potassium channels.
      G T Eddlestone, M Komatsu, L Shen and G W Sharp
      Molecular Pharmacology April 1995, 47 (4) 787-797;
    2. Unusual carbachol responses in RINm5F cells: evidence for a "distal" site of action in stimulus-secretion coupling.
      S H Tang, G C Yaney and G W Sharp
      Molecular Pharmacology April 1995, 47 (4) 863-870;

  7. Shen, L

    1. Mastoparan increases the intracellular free calcium concentration in two insulin-secreting cell lines by inhibition of ATP-sensitive potassium channels.
      G T Eddlestone, M Komatsu, L Shen and G W Sharp
      Molecular Pharmacology April 1995, 47 (4) 787-797;

  8. Shiao, L L

    1. Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
      M A Cascieri, L L Shiao, S G Mills, M MacCoss, C J Swain, H Yu, E Ber, S Sadowski, M T Wu and C D Strader
      Molecular Pharmacology April 1995, 47 (4) 660-665;

  9. Sperelakis, N

    1. Direct block of calcium channels by dioctanoylglycerol in pregnant rat myometrial cells.
      M Kusaka and N Sperelakis
      Molecular Pharmacology April 1995, 47 (4) 842-847;

  10. Srinivas, R V

    1. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates.
      P Aduma, M C Connelly, R V Srinivas and A Fridland
      Molecular Pharmacology April 1995, 47 (4) 816-822;

  11. Strader, C D

    1. Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
      M A Cascieri, L L Shiao, S G Mills, M MacCoss, C J Swain, H Yu, E Ber, S Sadowski, M T Wu and C D Strader
      Molecular Pharmacology April 1995, 47 (4) 660-665;

  12. Swain, C J

    1. Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
      M A Cascieri, L L Shiao, S G Mills, M MacCoss, C J Swain, H Yu, E Ber, S Sadowski, M T Wu and C D Strader
      Molecular Pharmacology April 1995, 47 (4) 660-665;

  13. Switzer, R L

    1. Inhibition of human 5-phosphoribosyl-1-pyrophosphate synthetase by 4-amino-8-(beta-D-ribofuranosylamino)-pyrimido[5,4-d]pyrimidine-5'- monophosphate: evidence for interaction at the ADP allosteric site.
      D W Fry, M A Becker and R L Switzer
      Molecular Pharmacology April 1995, 47 (4) 810-815;

T

  1. Tamura, T

    1. Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
      S Houssami, D M Findlay, C L Brady, T J Martin, R M Epand, E E Moore, E Murayama, T Tamura, R C Orlowski and P M Sexton
      Molecular Pharmacology April 1995, 47 (4) 798-809;

  2. Tang, S H

    1. Unusual carbachol responses in RINm5F cells: evidence for a "distal" site of action in stimulus-secretion coupling.
      S H Tang, G C Yaney and G W Sharp
      Molecular Pharmacology April 1995, 47 (4) 863-870;

  3. Taylor, D A

    1. Adaptive supersensitivity and the Na+/K+ pump in the guinea pig vas deferens: time course of the decline in the alpha 2 subunit.
      K M Hershman, D A Taylor and W W Fleming
      Molecular Pharmacology April 1995, 47 (4) 726-729;

  4. Traynor, J R

    1. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
      J R Traynor and S R Nahorski
      Molecular Pharmacology April 1995, 47 (4) 848-854;

  5. Treiger, B

    1. Cloning and expression of an endothelin receptor subtype B from human prostate that mediates contraction.
      M L Webb, C C Chao, M Rizzo, R A Shapiro, M Neubauer, E C Liu, C R Aversa, R J Brittain and B Treiger
      Molecular Pharmacology April 1995, 47 (4) 730-737;

  6. Tsu, R C

    1. Stimulation of type II adenylyl cyclase by chemoattractant formyl peptide and C5a receptors.
      R C Tsu, R A Allen and Y H Wong
      Molecular Pharmacology April 1995, 47 (4) 835-841;

U

  1. Uhler, M D

    1. Comparison of fura-2 imaging and electrophysiological analysis of murine calcium channel alpha 1 subunits coexpressed with novel beta 2 subunit isoforms.
      E Massa, K M Kelly, D I Yule, R L MacDonald and M D Uhler
      Molecular Pharmacology April 1995, 47 (4) 707-716;

W

  1. Watson, S P

    1. Ethylene glycol bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) and the tyrphostin ST271 inhibit phospholipase C in human platelets by preventing Ca2+ entry.
      S P Watson, A Poole and J Asselin
      Molecular Pharmacology April 1995, 47 (4) 823-830;

  2. Webb, M L

    1. Cloning and expression of an endothelin receptor subtype B from human prostate that mediates contraction.
      M L Webb, C C Chao, M Rizzo, R A Shapiro, M Neubauer, E C Liu, C R Aversa, R J Brittain and B Treiger
      Molecular Pharmacology April 1995, 47 (4) 730-737;

  3. Wong, Y H

    1. Stimulation of type II adenylyl cyclase by chemoattractant formyl peptide and C5a receptors.
      R C Tsu, R A Allen and Y H Wong
      Molecular Pharmacology April 1995, 47 (4) 835-841;

  4. Wu, J M

    1. Differential activation of human gastrin-releasing peptide receptor-mediated responses by bombesin analogs.
      J M Wu, D O Hoang and R I Feldman
      Molecular Pharmacology April 1995, 47 (4) 871-881;

  5. Wu, M T

    1. Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
      M A Cascieri, L L Shiao, S G Mills, M MacCoss, C J Swain, H Yu, E Ber, S Sadowski, M T Wu and C D Strader
      Molecular Pharmacology April 1995, 47 (4) 660-665;

  6. Wyrick, C D

    1. Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester.
      J W Boja, J L Cadet, T A Kopajtic, J Lever, H H Seltzman, C D Wyrick, A H Lewin, P Abraham and F I Carroll
      Molecular Pharmacology April 1995, 47 (4) 779-786;

Y

  1. Yaney, G C

    1. Unusual carbachol responses in RINm5F cells: evidence for a "distal" site of action in stimulus-secretion coupling.
      S H Tang, G C Yaney and G W Sharp
      Molecular Pharmacology April 1995, 47 (4) 863-870;

  2. Yu, H

    1. Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
      M A Cascieri, L L Shiao, S G Mills, M MacCoss, C J Swain, H Yu, E Ber, S Sadowski, M T Wu and C D Strader
      Molecular Pharmacology April 1995, 47 (4) 660-665;

  3. Yule, D I

    1. Comparison of fura-2 imaging and electrophysiological analysis of murine calcium channel alpha 1 subunits coexpressed with novel beta 2 subunit isoforms.
      E Massa, K M Kelly, D I Yule, R L MacDonald and M D Uhler
      Molecular Pharmacology April 1995, 47 (4) 707-716;

  4. Yurkow, E J

    1. Effects of chromium on basal and insulin-induced tyrosine phosphorylation in H4 hepatoma cells: comparison with phorbol-12-myristate-13-acetate and sodium orthovanadate.
      E J Yurkow and G Kim
      Molecular Pharmacology April 1995, 47 (4) 686-695;

Z

  1. Zhou, Q

    1. Extracellular ATP stimulates adenylyl cyclase and phospholipase C through distinct purinoceptors in NG108-15 cells.
      I Matsuoka, Q Zhou, H Ishimoto and H Nakanishi
      Molecular Pharmacology April 1995, 47 (4) 855-862;
Back to top

In this issue